BioLineRx to Present at 2013 Annual JMP Securities Healthcare Conference in New York
The BioLineRx presentation is currently scheduled to start at
In addition, investors attending the conference who wish to meet with
Dr. Savitsky and Mr. Serlin for a one-on-one meeting should contact
their
About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet
medical needs or with advantages over currently available therapies.
BioLineRx’s current portfolio consists of seven clinical stage
candidates: BL-1040, for prevention of pathological cardiac remodeling
following a myocardial infarction, which has been out-licensed to
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli
Government’s
Source: BioLineRx
KCSA Strategic Communications
Garth Russell / Todd Fromer
+1
212-896-1250 / +1 212-896-1250
grussell@kcsa.com
/ tfromer@kcsa.com
or
BioLineRx
Tsipi
Haitovsky
Public Relations
+972-3-6240871
tsipih@netvision.net.il